Treatment for adult patients with specific types of lymphoma and leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of a conditioning regimen consisting of thiotepa, cyclophosphamide, cladribine, and cytarabine in adult patients diagnosed with Burkitt lymphoma, lymphoblastic lymphoma, and acute lymphoblastic leukemia prior to undergoing autologous hematopoietic stem cell transplantation (auto-HSCT). It aims to include 28 patients who will receive this regimen as pre-transplant treatment, followed by a year of maintenance therapy to monitor outcomes. The study focuses on patients who have achieved specific remission criteria after initial chemotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Voluntarily sign the informed consent form, which must be signed by the patient himself.

  2\. ALL patients confirmed by bone marrow cell morphology, immunology, and genetics; 3. PH+ALL patients who achieve s3CMR (definition: achieve molecular biological remission in the early stage of initial treatment (within 3 months) and maintain remission); 4. Ph-B-ALL patients who have reached MRD- after 3 courses of chemotherapy and continue to be MRD-; adult patients with Burkitt lymphoma and lymphoblastic lymphoma confirmed by histopathology and molecular genetics; 5. Adult patients with Burkitt lymphoma and lymphoblastoma, if the bone marrow is not involved, can achieve PR or above after induction; if the bone marrow is involved at the time of initial diagnosis, 3 courses of chemotherapy are required to reach MRD- and continue to be MRD-.

  6\. Patients receiving autologous hematopoietic stem cell transplantation (auto-HSCT); 7. Age ≥18 years and ≤65 years old, male or female; 8. Eastern Cooperative Oncology Group Performance Status (ECOG-PS) score of 0-2;

Exclusion Criteria:

* 1\. Have a history of cancer and have received any treatment for this tumor in the past 3 years, except for superficial bladder cancer, basal cell or squamous cell carcinoma of the skin, cervical intraepithelial carcinoma (CIN), or prostate epithelium Internal carcinogenesis (PIN); 2. Known to be serologically positive for HIV, active hepatitis B, active hepatitis C virus or syphilis; 3. Suffering from mental illness or other conditions and unable to cooperate with the requirements of research treatment and monitoring; 4. Pregnant patients or patients who cannot take appropriate contraceptive measures during treatment; 5. Received hematopoietic stem cell transplantation within the past 1 year; 6. Active heart disease, defined as one or more of the following:

  1. Have a history of uncontrolled or symptomatic angina;
  2. Myocardial infarction less than 6 months from study enrollment;
  3. Have a history of arrhythmia that requires drug treatment or has severe clinical symptoms;
  4. Uncontrolled or symptomatic congestive heart failure (\>NYHA class 2);
  5. The ejection fraction is lower than the lower limit of the normal range. 7. Patients who meet the following criteria:

  <!-- -->

  1. Major surgery (except diagnostic surgery) is planned within 4 weeks before enrollment or during the study period, or the surgical wound has not fully healed before enrollment;
  2. Those who have received (attenuated) live vaccines within 4 weeks before enrollment;
  3. Patients with suspected active or latent tuberculosis;
  4. Participate in other clinical trials one month before enrollment 8. Those who the researcher believes are not suitable for enrollment

Where it's running

• The Fifth Affiliated Hospital of Sun Yat-sen University
  Zhuhai, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pediatric-style chemotherapy with venetoclax and immunotherapy for adults with Ph-negative acute lymphoblastic leukemia

  This treatment plan tests whether pediatric-style chemotherapy combined with venetoclax and optional immunotherapy helps people aged 14–60 with newly diagnosed Ph-negative ALL achieve remission and clear minimal residual disease.

  Recruiting Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07495631

• Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma

  This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07097363

• CX-5461 (Pidnarulex) for aggressive B‑cell lymphomas with MYC gene changes

  This trial tests whether the IV drug CX-5461 (Pidnarulex) is safe and can shrink or control aggressive B‑cell lymphomas that have MYC gene changes in adults who have already had other treatments.

  Recruiting at 8 sites Phase 1/2 National Cancer Institute (NCI) · Irvine, California and 7 other locations · NCT07069699

• Combined chemotherapy with venetoclax and stem cell transplant for adults with Ph-negative ALL

  This trial will try a treatment plan that gives intensive chemotherapy including venetoclax, followed by consolidation chemotherapy and possible allogeneic stem cell transplant, for adults aged 18–60 with Philadelphia chromosome–negative acute lymphoblastic leukemia.

  Recruiting Phase 2/3 Shanxi Bethune Hospital · Taiyuan, Shanxi · NCT07059156

• Comparing advanced and classical immunotherapy for lymphoma treatment

  This study is testing whether newer immunotherapy treatments for high-grade B cell lymphoma work better and are safer than traditional methods for adults who have already had treatment that didn't work.

  Recruiting at 2 sites Seoul St. Mary's Hospital · Seoul and 1 other locations · NCT06796517

• Combining BCL-2 inhibitors with HyperCVAD for treating T-lymphoblastic leukemia/lymphoma

  This study is testing whether combining BCL-2 inhibitors with the HyperCVAD treatment can help people who are newly diagnosed with T-lymphoblastic leukemia or lymphoma achieve better remission rates.

  Recruiting Phase 2 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai · NCT06598722

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.